Table 3.
Frequency of neutralizing antibodies and median percentage of neutralizing activity in positive cases, after the first and second dose of CoronaVac vaccination in SLE patients and controls*
| After vaccine 1st dose | After vaccine 2nd dose | |||
|---|---|---|---|---|
| Subjects with positive NAb | Neutralizing activity (%), median (IQR) | Subjects with positive NAb | Neutralizing activity (%), median (IQR) | |
| SLE patients (n = 213) | 58 (27.2) | 52.1 (38.1–71.4) | 131 (61.5) | 56.2 (41.3–77.2) |
| Controls (n = 52) | 19 (36.5) | 43.7 (37.6–77.4) | 44 (84.6) | 65.9 (48.2–79.6) |
| P (SLE patients × controls) | 0.232 | 0.786 | 0.002 | 0.132 |
*
Values are the no. (%) except where indicated otherwise. Positivity for neutralizing antibodies (NAb) defined as a neutralizing activity ≥30% (cPass sVNT Kit [GenScript]). IQR = interquartile range; SLE = systemic lupus erythematosus.